Preprint · OA
via OpenAlex
A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment
Miranda E. Orr, Eithan Kotkowski, Paulino Ramirez, Darcy Bair‐Kelps, Qianqian Liu, Charles Brenner, Mark S. Schmidt, Peter T. Fox, Anis Larbi, Crystal Tze Ying Tan, Glenn Choon Lim Wong, Jonathan Gelfond, Bess E Frost, Sara E Espinoza, Nicolas Musi
GeroScience · 2023 · ▲ 55 citations
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1007/s11357-023-00999-9
- Canonical
- link ↗
- Fetched
- 2026-11-07 MST
Cite this
APA
Orr, M.E., Kotkowski, E., Ramirez, P., Bair‐Kelps, D., Liu, Q., Brenner, C., Schmidt, M.S., Fox, P.T., Larbi, A., Tan, C.T.Y., Wong, G.C.L., Gelfond, J., Frost, B.E., Espinoza, S.E., Musi, N., & Powers, B. (2023). A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment. <em>GeroScience</em>. https://doi.org/10.1007/s11357-023-00999-9
Vancouver
Orr ME, Kotkowski E, Ramirez P, Bair‐Kelps D, Liu Q, Brenner C, et al. A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment. GeroScience. 2023. doi:10.1007/s11357-023-00999-9.
BibTeX
@unpublished{miranda2023Arando,
title = {A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment},
author = {Miranda E. Orr and Eithan Kotkowski and Paulino Ramirez and Darcy Bair‐Kelps and Qianqian Liu and Charles Brenner and Mark S. Schmidt and Peter T. Fox and Anis Larbi and Crystal Tze Ying Tan and Glenn Choon Lim Wong and Jonathan Gelfond and Bess E Frost and Sara E Espinoza and Nicolas Musi and Becky Powers},
journal = {GeroScience},
year = {2023},
doi = {10.1007/s11357-023-00999-9},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Biomed Industries, Inc. 2018
Open access · US-GOV
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of NA-831 in Alzheimer Patients With Mild Cognitive Impairment
NVP Healthcare 2026
Open access · US-GOV
36-week, Single-center, Randomized, Double-blind, Parallel-design, Placebo-controlled Trial to Determine the Safety and Efficacy of NVP-NK4146 in Patients With Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
University of Colorado, Boulder 2015
Open access · US-GOV
Safety & Efficacy of Nicotinamide Riboside Supplementation for Improving Physiological Function in Middle-Aged and Older Adults
Bristol-Myers Squibb 2025
Open access · US-GOV
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated With Mild to Moderate Alzheimer's Disease (MINDSET 2)
Oregon Research Institute 2023
Open access · US-GOV
Dual-Task Training Exercise to Reduce Falls in Older Adults With Mild Cognitive Impairment
New York State Psychiatric Institute 2010
Open access · US-GOV